Surrozen, Inc. (NASDAQ:SRZN) Short Interest Down 21.6% in October

Surrozen, Inc. (NASDAQ:SRZN) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 34,900 shares, a decrease of 21.6% from the October 15th total of 44,500 shares. Currently, 1.5% of the shares of the company are short sold. Based on an average daily volume of 18,300 shares, the days-to-cover ratio is currently 1.9 days.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Armistice Capital LLC bought a new position in shares of Surrozen during the 2nd quarter valued at approximately $2,080,000. Nantahala Capital Management LLC bought a new position in shares of Surrozen in the second quarter worth approximately $2,050,000. Stonepine Capital Management LLC purchased a new stake in shares of Surrozen in the second quarter worth $724,000. Finally, CVI Holdings LLC purchased a new stake in shares of Surrozen in the second quarter worth $711,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

Surrozen Stock Performance

Shares of NASDAQ SRZN traded down $0.47 during trading on Friday, reaching $9.01. 4,267 shares of the company traded hands, compared to its average volume of 14,597. The firm has a 50 day simple moving average of $10.10 and a 200-day simple moving average of $9.77. Surrozen has a 52-week low of $5.61 and a 52-week high of $16.19.

Surrozen (NASDAQ:SRZN) last posted its earnings results on Wednesday, November 6th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($2.77) by $2.33. The company had revenue of $10.00 million during the quarter. As a group, analysts anticipate that Surrozen will post -7.16 EPS for the current year.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.